Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 4:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 31 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Acute Upper Respiratory Tract Infection Clear all
Completed Phase 2Phase 3 Interventional Results available

Safety and Efficacy of Mucinex and IR Guaifenesin the Treatment of Symptoms of Acute Upper Respiratory Tract Infections

NCT01537081
View directory record Official record
Conditions
Acute Upper Respiratory Tract Infection
Interventions
Mucinex, Immediate-release Guaifenesin, Placebo
Drug
Lead sponsor
Reckitt Benckiser LLC
Industry
Eligibility
12 Years and older
Enrollment
2,810 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
43
States / cities
Hoover, Alabama • Bell Gardens, California • Harbor City, California + 38 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2013 · Synced Sep 28, 2026, 4:52 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection

NCT03656510
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
JNJ-53718678, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
28 Days to 3 Years
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
14
States / cities
Madera, California • Ventura, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Sep 28, 2026, 4:52 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

HAIQU (Hospital AIr QUality)

NCT07670117
View directory record Official record
Conditions
Acute Respiratory Tract Infection
Interventions
Self-swab test
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
850 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
3
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 28, 2026, 4:52 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Rilematovir in Infants and Children and Subsequently in Neonates Hospitalized With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus (RSV)

NCT04583280
View directory record Official record
Conditions
Respiratory Tract Infections
Interventions
Rilematovir, Rilematovir X mg/kg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
1 Day to 5 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Orlando, Florida • Jackson, Mississippi • The Bronx, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Sep 28, 2026, 4:52 AM EDT
Completed Not applicable Interventional Results available

Study of Count Coughs in Subjects With Acute Upper Respiratory Tract Infections

NCT01062256
View directory record Official record
Conditions
Infection
Interventions
Placebo, Guaifenesin, Buckwheat Honey
Drug · Other
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
2
States / cities
Indianapolis, Indiana • Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 24, 2013 · Synced Sep 28, 2026, 4:52 AM EDT
Completed Phase 3 Interventional Results available

Placebo-Controlled Onset-of-Action Study of Flurbiprofen Utilizing the Double-Stopwatch Method

NCT01986361
View directory record Official record
Conditions
Acute Pharyngitis, Sore Throat
Interventions
flurbiprofen, placebo
Drug
Lead sponsor
Reckitt Benckiser LLC
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 27, 2017 · Synced Sep 28, 2026, 4:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Broad Implementation of Outpatient Stewardship

NCT05127161
View directory record Official record
Conditions
Acute Respiratory Tract Infection, Otitis Media, Pharyngitis, Acute Sinusitis
Interventions
Broad Implementation of Outpatient Stewardship (BIOS) intervention
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
6 Months to 12 Years
Enrollment
1,032 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
5
States / cities
Plantation, Florida • Cleveland, Ohio • Hershey, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Sep 28, 2026, 4:52 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Wide Scale Monitoring for Acute Respiratory Infection Using a Mobile-Based Study Platform

NCT04663776
View directory record Official record
Conditions
Covid19, Influenza, Respiratory Tract Infections, Acute Respiratory Tract Infection, Acute Respiratory Distress Syndrome
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
18 Years and older
Enrollment
16,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 6, 2022 · Synced Sep 28, 2026, 4:52 AM EDT
Completed Not applicable Interventional

C-reactive Protein (CRP)-Guided Management Algorithm for Adults With Acute Cough

NCT00221351
View directory record Official record
Conditions
Cough
Interventions
CRP point of care testing
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
2
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated May 22, 2011 · Synced Sep 28, 2026, 4:52 AM EDT
Completed No phase listed Observational

A Rapid Test for Acute Respiratory Illness

NCT03192072
View directory record Official record
Conditions
Respiratory Tract Infection Acute, Transcriptome, Virus Disease, Bacterial Infections
Interventions
Host Gene Expression
Diagnostic Test
Lead sponsor
Duke University
Other
Eligibility
2 Years and older
Enrollment
783 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
10
States / cities
Davis, California • Boston, Massachusetts • Newton, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated May 26, 2020 · Synced Sep 28, 2026, 4:52 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Vitamin A and Zinc: Prevention of Pneumonia (VAZPOP) Study

NCT00228254
View directory record Official record
Conditions
Pneumonia, Diarrhea, Acute Upper Respiratory Tract Infections
Interventions
Zinc (12.5 mg/day), vitamin A 10,000 IU per week
Drug
Lead sponsor
Tufts University
Other
Eligibility
6 Months to 36 Months
Enrollment
2,582 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 27, 2005 · Synced Sep 28, 2026, 4:52 AM EDT
Completed No phase listed Observational

Impact of Respiratory Pathogens in Infants

NCT01789268
View directory record Official record
Conditions
Respiratory Tract Infection
Interventions
Respiratory Inductive Plethysmography
Device
Lead sponsor
University of Rochester
Other
Eligibility
0 Days to 3 Years
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 1, 2022 · Synced Sep 28, 2026, 4:52 AM EDT
Completed Not applicable Interventional Results available

Procalcitonin Antibiotic Consensus Trial (ProACT)

NCT02130986
View directory record Official record
Conditions
Lower Respiratory Tract Infection (LRTI)
Interventions
Procalcitonin level, Results of procalcitonin (PCT) level to treating clinician, Provide procalcitonin guideline to treating clinician, Telephone Visit
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
1,664 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
13
States / cities
Birmingham, Alabama • Phoenix, Arizona • Orange, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2019 · Synced Sep 28, 2026, 4:52 AM EDT
Active, not recruiting Not applicable Interventional

Rapid Diagnosis of Viral Acute Respiratory Infection to Decrease Unnecessary Antibiotic Utilization in the Emergency Department (RADIATE)

NCT06271655
View directory record Official record
Conditions
Acute Respiratory Infection, Viral Infection, Upper Respiratory Tract Infections
Interventions
SPOTFIRE R Panel
Device
Lead sponsor
Christopher Payette
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Sep 28, 2026, 4:52 AM EDT
Not listed Phase 1 Interventional

Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831

NCT04480333
View directory record Official record
Conditions
Covid19, Corona Virus Infection, Severe Acute Respiratory Syndrome, Severe Acute Respiratory Infection, Severe Acute Respiratory Syndrome (SARS) Pneumonia, Severe Acute Respiratory Syndrome of Upper Respiratory Tract, Neurodegeneration, Neuroinflammatory Response
Interventions
Drug: NA-831 - 0.10 mg/kg, Placebo- 0.10 mg/kg, Drug: NA-831 - 0.20 mg/kg, Placebo- 0.20 mg/kg, Drug: GS-5734 - 1.00 mg/kg, Placebo- 1.00 mg/kg, Drug: GS-5734 - 2.00 mg/kg, Placebo- 2.00 mg/kg, Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg), Placebo 0.10 mg + 1.00 mg/kg, Drugs: NA-831 (0.20 mg/kg) plus GS-5734 (2.00 mg/kg), Placebo 0.20 mg + 2.00 mg/kg
Drug · Combination Product
Lead sponsor
Biomed Industries, Inc.
Industry
Eligibility
21 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Sunnyvale, California
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Sep 28, 2026, 4:52 AM EDT
Completed Phase 3 Interventional Results available

BAY12-8039: 5 Days for Sinusitis vs Placebo

NCT00492024
View directory record Official record
Conditions
Sinusitis
Interventions
Moxifloxacin (Avelox, BAY12-8039), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
51
States / cities
Birmingham, Alabama • Northport, Alabama • Jonesboro, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Sep 28, 2026, 4:52 AM EDT
Completed Phase 2 Interventional Results available

Mucinex Exploratory Cold Study

NCT01046136
View directory record Official record
Conditions
Common Cold
Interventions
guaifenesin (Mucinex), placebo
Drug
Lead sponsor
Reckitt Benckiser Inc.
Industry
Eligibility
12 Years and older
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Bellevue, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 29, 2020 · Synced Sep 28, 2026, 4:52 AM EDT
Completed Not applicable Interventional

The RAPID Trial: Assessing Point-of-care Influenza and Other Respiratory Virus Diagnostics

NCT03756753
View directory record Official record
Conditions
Respiratory Pathogens, Upper Respiratory Tract Illness, Lower Respiratory Tract Illness, Acute Respiratory Infection
Interventions
Results available to provider
Diagnostic Test
Lead sponsor
University of Colorado, Denver
Other
Eligibility
1 Month to 18 Years
Enrollment
913 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Sep 28, 2026, 4:52 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years

NCT03694392
View directory record Official record
Conditions
Influenza, Pneumonia, Lower Respiratory Tract Infection, Acute Myocardial Infarction, Congestive Heart Failure, Stroke
Interventions
Flublok Quadrivalent, Standard Dose Inactivated Influenza Vaccine (SD-IIV)
Biological
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years to 64 Years
Enrollment
2,776,278 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Apr 7, 2025 · Synced Sep 28, 2026, 4:52 AM EDT
Terminated Phase 4 Interventional Results available

Acute Cough Study In Children

NCT01257542
View directory record Official record
Conditions
Common Cold, Infections, Upper Respiratory Tract
Interventions
Dextromethorphan, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 11 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Pinellas Park, Florida • Indianapolis, Indiana • Gresham, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2012 · Synced Sep 28, 2026, 4:52 AM EDT
Completed Not applicable Interventional

Using Behavioral Science to Reduce Inappropriate Antibiotic Use in Acute Care Settings

NCT03711292
View directory record Official record
Conditions
Antimicrobial Stewardship, Acute Bronchitis, Upper Respiratory Infection
Interventions
Antibiotic Stewardship
Behavioral
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
21 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2023 · Synced Sep 28, 2026, 4:52 AM EDT
Not listed Not applicable Interventional

Dialogue Around Respiratory Illness Treatment

NCT02943551
View directory record Official record
Conditions
Respiratory Disease, Acute Respiratory Infection, Respiratory Infection, Upper Respiratory Infection
Interventions
Online Tutorial, Webinars, Booster Sessions, Feedback Reports, Parent Survey
Other
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
6 Months to 10 Years
Enrollment
2,728 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
20
States / cities
Paragould, Arkansas • Eureka, California • Durango, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Sep 28, 2026, 4:52 AM EDT
Recruiting Phase 2 Interventional

A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease

NCT07214571
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
S-337395, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
36
States / cities
Los Angeles, California • Modesto, California • Toluca Lake, California + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 28, 2026, 4:52 AM EDT
Completed Not applicable Interventional Results available

Urgent Care Management of Respiratory Illness Enabled With Novel Testing Pathway

NCT05467007
View directory record Official record
Conditions
Viral Infection, Acute Respiratory Infection, Upper Resp Tract Infection
Interventions
BioFire® Respiratory Panel 2.1-EZ
Diagnostic Test
Lead sponsor
Andrew Meltzer
Other
Eligibility
7 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 28, 2026, 4:52 AM EDT